214680.Kq
The company operates in the healthcare equipment industry, specializing in the design, development, and sale of advanced medical equipment and technology.
Business. The company operates in the healthcare equipment industry, specializing in the design, development, and sale of advanced medical equipment and technology.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare equipment industry, specializing in the design, development, and sale of advanced medical equipment and technology.
The company's capital structure is characterized by a debt-to-equity ratio of 1.15, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 2.03, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -20.13 billion KRW, and its free cash flow is also negative at -19.74 billion KRW, signaling potential liquidity constraints.
Profitability metrics show a challenging performance, with a return on equity of -31.31% and a return on assets of -11.9%, both significantly below the industry median for the Advanced Medical Equipment & Technology sector. The company reported a net loss of 24.03 billion KRW and an operating loss of 15.31 billion KRW, indicating a need for operational improvements or cost reductions to align with industry standards.
The company's revenue is concentrated in a single geographic and product segment, as disclosed in its financial statements, with no material diversification across regions or product lines. This concentration increases exposure to regional economic shifts and product-specific demand fluctuations, which could impact revenue stability.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Historical revenue data shows a total of 116.30 billion KRW, but without a clear trend or direction, it is difficult to assess future performance. The company's capital expenditure of -6.77 billion KRW suggests a reduction in investment in new projects or infrastructure, which may affect long-term growth potential.
Risk factors include a medium liquidity risk due to negative operating and free cash flows, and a key flag indicating that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. However, the company's financial performance and liquidity position may require close monitoring for potential capital structure adjustments.
Recent events include the filing of the latest financial statements, which disclose the company's current financial position and performance. No recent earnings call transcripts or other material events were reported in the available data.
- The company is experiencing a net loss and operating loss, indicating a need for operational improvements.
- The debt-to-equity ratio of 1.15 suggests a moderate reliance on debt financing.
- The company's liquidity position is medium, with a current ratio of 2.03.
- The company's profitability metrics are significantly below the industry median.
- The company's revenue is concentrated in a single segment, increasing exposure to regional and product-specific risks.
- The company's capital expenditure is negative, suggesting a reduction in investment in new projects.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 214680.KQ Market data — financials · 2026-05-26